Werewolf Therapeutics Q3 net loss $13.8M; cash $170.4M; Merck collaboration for WTX-124

Werewolf Therapeutics, Inc.

2021-Q3 EPS reported -$11.89

Net loss of $13.8M versus $6.1M in Q3 2020; R&D expenses $9.8M, G&A $4.0M.
Cash and equivalents $170.4M, up from $92.6M at year-end 2020; runway through Q2 2023.
Entered clinical trial collaboration with Merck to evaluate WTX-124 + KEYTRUDA in solid tumors.
On track to file INDs for WTX-124 and WTX-330 in first half of 2022.
Appointed Meeta Chatterjee, Ph.D., to board of directors in October 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.